• Search
  • Helpdesk
  • Sales contact

Tackling the specificities of NASH/MASH clinical trials

26 March 2024

Integrating PROs into studies on MASH, also known as NASH, is crucial. 
MASH is a debilitating chronic illness that significantly impairs patients’ quality of life, affecting their daily routines, work, and mobility.

  • Patient-centric appraisals are needed in the quest for treatments
  • Integrating PROs in MASH studies expands insights beyond MASH metrics, and helps understand MASH patients’ concerns


At Kayentis, we have the full capability to run your MASH studies successfully:

  • We have extensive experience in MASH and hepatic disorders research
  • We offer an enhanced patient-centric eCOA data entry
  • We are a key partner to biotech and big pharma companies
 
Download the case study 👇

Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

Mobile in Clinical Trials

16 SEPT 2024 • Philadelphia, USA
https://mobileinclinicaltrials.com/

DPharm 2024

17-18 SEPT 2024 • Philadelphia, USA
https://dpharmconference.com/   

SCDM 2024

29 SEPT - 2 OCT 2024 • Boston, USA
https://scdmlive.org/annual-conference-2024/      

ISOQOL 2024

13-16 OCT 2024 • Cologne, Germany
https://www.isoqol.org/    

CNS SUMMIT 2024

10-13 NOV 2024 • Cologne, Germany
https://cnssummit.org/the-summit/  

DMB 2024

13 NOV 2024 • Paris, France
https://dmb-asso.org/

SCOPE 2025

FEB 3-6 2025 • Orlando, USA
Booth #931 https://www.scopesummit.com/